Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

Teva could kill 3 birds with one $6B deal for India's Cipla

08.05.2014 / Fierce Pharma

Last week, Teva CEO Erez Vigodman said the Israeli company was looking to refocus on its generics business, bolster its emerging markets presence and become a major player in the global biosimilars race. And now, he may be eyeing a $6 billion deal that could help accomplish all three goals.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: